Skip to content
Menu

HC Wainwright & Co. Maintains Buy on Acurx Pharmaceuticals, Lowers Price Target to $11

Benzinga Newsdesk 1 week ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Matthew Keller maintains Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and lowers the price target from $31 to $11.

HC Wainwright & Co. analyst Matthew Keller maintains Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and lowers the price target from $31 to $11.

Read at benzinga.com